ClinicalTrials.gg

Program

rozanolixizumab

Also written as “Rozanolixizumab”, “UCB7665” and “UCB7665 Intravenous 1”.

Its studies are mostly in Myasthenia Gravis · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease · Fibromyalgia, led by UCB.

Furthest: phase 4, since Nov 17, 202523 company-led studies, 5 open or runningNext primary completion: May 6, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
UCB235 open or runningphase 4since Nov 17, 2025Aug 18, 2014May 6, 2027phase 3 · NCT05063162

Also a collaborator on its studies: parexel.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 10 studies since Aug 18, 2014.

  1. Oct 15, 2020Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT04596995 · 43 enrolled · United States, China, Georgia and more
  2. Nov 5, 2020Phase 3 study in Myasthenia GravisNCT04650854 · 165 enrolled · United States, Canada, Czechia and more
  3. Mar 30, 2021Phase 1 study in Healthy Study ParticipantsNCT04828343 · 32 enrolled · United Kingdom
  4. May 3, 2021Phase 2 study in Leucine-Rich Glioma Inactivated 1 Autoimmune EncephalitisNCT04875975 · 12 enrolled · United States, Australia, Belgium and more
  5. Sep 21, 2021Phase 3 study in Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseNCT05063162 · 113 enrolled · United States, Australia, Belgium and more
  6. Nov 30, 2022Phase 2 study in FibromyalgiaNCT05643794 · 63 enrolled · United Kingdom
  7. Jan 4, 2023Phase 3 study in Myasthenia GravisNCT05681715 · 62 enrolled · United States, Canada, Georgia and more
  8. Sep 25, 2023Phase 3 study in Myasthenia GravisNCT06149559 · 14 enrolled · Italy, Japan, Poland and more
  9. Jul 22, 2024Phase 3 study in Myasthenia GravisNCT06540144 · 13 enrolled · Italy, Japan, Poland and more
  10. Dec 2, 2024Phase 1 study in Healthy ParticipantsNCT06720714 · 15 enrolled · United States
  11. Nov 17, 2025Phase 4 study in Myasthenia GravisNCT07246564 · 40 enrolled · China
  12. Mar 5, 20262 phase 3 studies in Myasthenia GravisNCT07463521, NCT07465289
  13. Oct 16, 2026Primary completion moved from 2027-08-17 to 2027-10-05Date moved laterphase 3 · +2 months · NCT06540144
  14. Oct 27, 2026Primary completion moved from 2031-01-23 to 2031-03-17Date moved laterphase 3 · +2 months · NCT07465289

Ahead

  1. May 6, 2027Primary completion: phase 3 study in Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseNCT05063162
  2. Oct 5, 2027Primary completion: phase 3 study in Myasthenia GravisNCT06540144
  3. Oct 15, 2027Primary completion: phase 4 study in Myasthenia GravisNCT07246564
  4. Dec 1, 2028Primary completion: phase 3 study in Myasthenia GravisNCT07463521

TargetBeta

FCGRT →read by rule
“IgG receptor FcRn large subunit p51 inhibitor”ChEMBL 37, by rule

Other programs on FCGRT

ProgramCompanyFurthest phaseStudies
efgartigimod alfaruleargenxphase 448
nipocalimabruleJohnson & Johnsonphase 324
batoclimabruleimmunovant-sciences-gmbhphase 318

Studies

All 23 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07465289Myasthenia Gravis · United States, China, France and more3RecruitingMar 17, 2031100
NCT07463521Myasthenia Gravis · United States, Canada, China and more3RecruitingDec 1, 2028120
NCT07246564Myasthenia Gravis · China4Active, not recruitingOct 15, 202740
NCT06720714Healthy Participants · United States1CompletedMay 12, 202515
NCT06540144Myasthenia Gravis · Italy, Japan, Poland and more3Active, not recruitingOct 5, 202713
NCT06149559Myasthenia Gravis · Italy, Japan, Poland and more3CompletedOct 5, 202614
NCT05681715Myasthenia Gravis · United States, Canada, Georgia and more3CompletedApr 23, 202462
NCT05643794Fibromyalgia · United Kingdom2CompletedMay 28, 202463
NCT05063162Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease · United States, Australia, Belgium and more3Active, not recruitingMay 6, 2027113
NCT04875975Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis · United States, Australia, Belgium and more2TerminatedMar 8, 202412
NCT04828343Healthy Study Participants · United Kingdom1CompletedApr 11, 202232
NCT04650854Myasthenia Gravis · United States, Canada, Czechia and more3CompletedJan 25, 2024165
NCT04596995Purpura, Thrombocytopenic, Idiopathic · United States, China, Georgia and more3TerminatedDec 21, 202243
NCT04224688Purpura, Thrombocytopenic, Idiopathic · United States, Bulgaria, China and more3TerminatedApr 25, 202230
NCT04200456Purpura, Thrombocytopenic, Idiopathic · United States, Bulgaria, France and more3TerminatedMar 21, 202233
NCT04124965Myasthenia Gravis · United States, Canada, Czechia and more3CompletedSep 1, 202171
NCT04051944Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Belgium, Denmark and more2CompletedNov 10, 202121
NCT03971422Myasthenia Gravis · United States, Belgium, Canada and more3CompletedAug 31, 2021200
NCT03861481Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Belgium, Denmark and more2CompletedMar 31, 202134
NCT03859219Healthy-volunteers · United Kingdom1CompletedApr 28, 202065
NCT03052751Myasthenia Gravis · United States, Belgium, Canada and more2CompletedMay 31, 201843
NCT02718716Thrombocytopenia · Australia, Bulgaria, Czechia and more2CompletedFeb 4, 201966
NCT02220153Healthy · United Kingdom1CompletedSep 201541

How it is read

Names in the registry

  • “Rozanolixizumab”, 16 entries
  • “rozanolixizumab”, 4 entries
  • “UCB7665”, 2 entries
  • “UCB7665 Intravenous 1”, 1 entry
  • “UCB7665 Intravenous 2”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.